Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 4/2013

01-12-2013 | Osteoporosis and Cancer (P Taxel, Section Editor)

Osteoporosis after Stem Cell Transplantation

Authors: Brian L. McClune, Navneet S. Majhail

Published in: Current Osteoporosis Reports | Issue 4/2013

Login to get access

Abstract

With long-term survival for recipients of autologous and allogeneic hematopoietic cell transplantation (HCT) increasing, the recognition of late complications such as decreased bone mineral density leading to osteoporosis (OP) has also increased. With an incidence that is reported to affect as many 50 % of allo HCT recipients, studies continue to mount supporting the need and success in treatment of this HCT complication. In this review, we highlight the major pathological mechanisms behind the development of OP, its diagnosis, and the literature supporting consensus treatment recommendations while noting areas of uncertainty that need further research.
Literature
1.
Hahn T, McCarthy PL, Hasselbroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.PubMedCrossRef
2.
•• Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol. 2013;30:3665–74. Good review of bone loss specifically related to the general oncology patient.CrossRef
3.
Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:165–74.PubMedCrossRef
4.
Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1993;140:4382–9.CrossRef
5.
Castelo-Branco C, Rovira M, Pons F, et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas. 1996;23:307–12.PubMedCrossRef
6.
Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol. 2005;23:6596–606.PubMedCrossRef
7.
Massenkeil G, Fiene C, Rosen O, et al. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia. 2001;15:1701–5.PubMedCrossRef
8.
Robin M, Guardiola P, Devergie A, et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia. 2005;19:1613–20.PubMedCrossRef
9.
Tauchmanova L, De Simone G, Musella T, et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37:81–8.PubMed
10.
Kananen K, Volin L, Laitinen K, et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005;90:3877–85.PubMedCrossRef
11.
Tauchmanova L, Selleri C, Esposito M, et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int. 2003;14:1013–9.PubMedCrossRef
12.
Valimaki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant. 1999;23:355–61.PubMedCrossRef
13.
Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006;91:3835–43.PubMedCrossRef
14.
Yao S, Smiley SL, West K, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous vs allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:1130–7.PubMedCrossRef
15.
Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103:3635–43.PubMedCrossRef
16.
Tauchmanova L, Colao A, Lombardi G, et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007;92:4536–45.PubMedCrossRef
17.
Savani BN, Donohue T, Kozanas E, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:517–20.PubMedCrossRef
18.
19.
Nguyen ND, Eisman JA, Center JR, et al. Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab. 2007;92:955–62.PubMedCrossRef
20.
Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–93.PubMedCrossRef
21.
22.
Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer: a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18:1439–50.PubMedCrossRef
23.
Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–57.PubMedCrossRef
24.
Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force report: bone health in cancer care. J Natl Compr Cancer Netw. 2009;7 Suppl 3:S1–S32.
25.
Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2005;90:627–34.PubMedCrossRef
26.
Chae YS, Kim JG, Moon JH, et al. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant. 2009;44:35–41.PubMedCrossRef
27.
D’Souza AB, Grigg AP, Szer J, Ebeling PR. Zoledronic acid prevents bone loss after allogeneic hemopoietic stem cell transplantation. Intern Med J. 2006;36:600–3.PubMedCrossRef
28.
Moyer VA. U.S. Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158:691–6.PubMed
29.
Sproat L, Bolwell B, Rybicki L, et al. Vitamin D level after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011;17:1079–83.PubMedCrossRef
30.
Joseph RW, Alousi A, Konda B, et al. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol. 2011;86:954–6.PubMedCrossRef
31.
North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19:257–71.
32.
•• Hari P, Defore TE, Vesole DH, et al. Intermittent zolendronic acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1361–7. Accessed July 5, 2013. Latest randomized trial supporting the use of zolendronic acid in HCT patients.
33.
Ganguly S, Divine CL, Aljitawi OS, Abhyankar S, et al. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Transplant. 2012;26:447–53.PubMedCrossRef
34.
Hausmann A, Hill W, Stemmler HJ, et al. Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic acid. Chemother Res Pract. 2012. [Published online ahead of print April 10, 2012]. Accessed July 5, 2013.
35.
Chestnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267–76.CrossRef
36.
Traynor K. Experts recommend against calcitonin-salmon for postmenopausal osteoporosis. Am J Health Syst Pharm. 2013;70:648–50.PubMedCrossRef
37.
Andrews EB, Gilsenan AW, Midkiff K, et al. The US post-marketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429–37.PubMedCrossRef
38.
Watanabe A, Yoneyama S, Nakajima M, et al. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1–34)). J Toxicol Sci. 2012;37:617–29.PubMedCrossRef
39.
Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838–45.PubMedCrossRef
40.
Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785–93.PubMedCrossRef
41.
Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–15.PubMedCrossRef
42.
Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006;91:2882–7.PubMedCrossRef
43.
•• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet. 2013;382:50–6. One of the first publications on the rational use of newer agents to improve BMD in non-HCT patients.PubMedCrossRef
44.
•• Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:348–71. Excellent comprehensive review of guidelines for post-HCT survivorship.PubMedCrossRef
45.
• McClune BL, Polgreen LE, Burmeister LA, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;46:1–9. Single center review and recommendations for OP/osteopenia screening and treatment in a HCT recipients.PubMedCrossRef
Metadata
Title
Osteoporosis after Stem Cell Transplantation
Authors
Brian L. McClune
Navneet S. Majhail
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 4/2013
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-013-0180-1

Other articles of this Issue 4/2013

Current Osteoporosis Reports 4/2013 Go to the issue

Epidemiology and Pathophysiology (RA Adler, Section Editor)

Recent Advances: Osteoporosis in the “Oldest Old”

Quality of Care in Osteoporosis (SL Silverman, Section Editor)

Review of New Guidelines for the Management of Glucocorticoid Induced Osteoporosis

Osteoporosis and Cancer (P Taxel, Section Editor)

Skeletal Manifestations of Treatment of Breast Cancer

Quality of Care in Osteoporosis (SL Silverman, Section Editor)

Commentary: Measuring Quality of Care in Osteoporosis

The Why and How of Fracture Liaison Services (SL Silverman, Section Editor)

Fracture Liaison Services in an Open System: How was it Done? What Were the Barriers and How Were They Overcome?

Osteoporosis and Cancer (P Taxel, Section Editor)

Effects of Radiation on Bone